CA2015585A1 - Methode et compose pour le traitement des troubles dermatologiques a mediation par les mastocytes - Google Patents

Methode et compose pour le traitement des troubles dermatologiques a mediation par les mastocytes

Info

Publication number
CA2015585A1
CA2015585A1 CA2015585A CA2015585A CA2015585A1 CA 2015585 A1 CA2015585 A1 CA 2015585A1 CA 2015585 A CA2015585 A CA 2015585A CA 2015585 A CA2015585 A CA 2015585A CA 2015585 A1 CA2015585 A1 CA 2015585A1
Authority
CA
Canada
Prior art keywords
compositions
mast cell
mediated
treatment
dermatologic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2015585A
Other languages
English (en)
Other versions
CA2015585C (fr
Inventor
Phillip Frost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Branded Pharmaceutical Products R&D Inc
Original Assignee
Baker Cummins Dermatologicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Dermatologicals Inc filed Critical Baker Cummins Dermatologicals Inc
Publication of CA2015585A1 publication Critical patent/CA2015585A1/fr
Application granted granted Critical
Publication of CA2015585C publication Critical patent/CA2015585C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002015585A 1989-07-10 1990-04-27 Methode et compose pour le traitement des troubles dermatologiques a mediation par les mastocytes Expired - Fee Related CA2015585C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US377,572 1989-07-10
US07/377,572 US4923875A (en) 1989-07-10 1989-07-10 Method for treatment of mast cell-mediated dermatologic disorders

Publications (2)

Publication Number Publication Date
CA2015585A1 true CA2015585A1 (fr) 1991-01-10
CA2015585C CA2015585C (fr) 1995-10-24

Family

ID=23489660

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002015585A Expired - Fee Related CA2015585C (fr) 1989-07-10 1990-04-27 Methode et compose pour le traitement des troubles dermatologiques a mediation par les mastocytes

Country Status (4)

Country Link
US (1) US4923875A (fr)
EP (1) EP0409392A3 (fr)
JP (1) JPH07557B2 (fr)
CA (1) CA2015585C (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994466A (en) * 1990-06-14 1991-02-19 Baker Cummins Pharmaceuticals, Inc. Method of treatment for multiple sclerosis
US5057322A (en) * 1990-08-10 1991-10-15 Baker Cummins Dermatologicals, Inc. Method of treating mast cell disease
MX9604208A (es) * 1994-03-21 1998-05-31 John Brown Thomsen Gel para el tratamiento de enfermedades de la piely para la desinfeccion de la piel.
US6506789B2 (en) 1998-06-03 2003-01-14 Shionogi & Co., Ltd. Methods for the treatment of itching comprising administering PGD2 receptor antagonist
CN1198649C (zh) * 1998-06-03 2005-04-27 盐野义制药株式会社 用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
PL2196206T3 (pl) * 2007-10-05 2020-02-28 Toray Industries, Inc. Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną
WO2009047562A1 (fr) * 2007-10-08 2009-04-16 Serentis Limited Procédés et compositions utilisés dans le traitement du prurit
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
GB0814043D0 (en) * 2008-07-31 2008-09-10 Serentis Ltd The treatment of skin disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416886A (en) * 1981-07-29 1983-11-22 Dermall Limited Method of treating pruritis and composition therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
JPS63501717A (ja) * 1985-10-29 1988-07-14 ベーカー・カミンス・デルマトロジカルス・インコーポレーテッド 抗原誘発性アレルギ−反応を阻止するための方法および組成物
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
EP0375689B1 (fr) * 1987-06-01 1992-08-12 Warner-Lambert Company Composition pharmaceutique adaptee a l administration transdermique d'un medicament opioid.
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis

Also Published As

Publication number Publication date
JPH03204815A (ja) 1991-09-06
EP0409392A3 (en) 1991-09-18
CA2015585C (fr) 1995-10-24
EP0409392A2 (fr) 1991-01-23
US4923875A (en) 1990-05-08
JPH07557B2 (ja) 1995-01-11

Similar Documents

Publication Publication Date Title
IL94490A0 (en) Stable,cosmetically acceptable topical gel formulation and method of treatment for acne
CA2159985A1 (fr) Methodes d'utilisation de l'hesperetine pour le controle du sebum et le traitement de l'acne
AU5003990A (en) Method and device for the controlled local, non-invasive application of dc pulses to human tissues
DE69720053T2 (de) Verminderung des haarwuchses
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
IL99291A (en) Cosmetic preparations
CA2252900A1 (fr) Composition cosmetique pour regenerer la peau sans l'irriter
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
ITMI950575A0 (it) Preparati igienici e cosmetici per prevenire e trattare malattie della pelle nonche' procedimento per il loro ottenimento
CA2015585A1 (fr) Methode et compose pour le traitement des troubles dermatologiques a mediation par les mastocytes
IL94267A0 (en) Compositions for treating skin disorders containing ketoconazole and their preparation
EP0352025A3 (fr) Utilisation de nalméfène pour le traitement de la rhinite allergique
DE69315927D1 (de) Kosmetische Zusammensetzung, die einen Lipidstoff und eine Hydroxy - oder Ketofettsäure enthält
DE69030923T2 (de) Haarwuchsmittel
ZA957507B (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
ZA898605B (en) Compositions for topical treatment of skin diseases
DE3685696D1 (de) Melatoninhaltige mittel sowie deren verwendungen.
CA2190377A1 (fr) Compositions de traitement topique des vergetures comprenant de l'acide alpha-hydroxy
JP2002506805A (ja) 保湿組成物
WO1994004184A3 (fr) Procede pour ralentir le vieillissement de la peau
CA2065412A1 (fr) Methode permettant de prevenir les vergetures et d'en reduire la taille
CA2322745A1 (fr) Procede pour traiter les douleurs liees a un nevrome
AU4678893A (en) Compositions and methods for topical treatment of skin lesions
CA2132528A1 (fr) Agent utilise comme anti-irritant
IL136807A0 (en) Topical carbamazepine formulation and methods of use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed